Company Overview and News

0
Ontex UK Optimizes Home Delivery with Descartes’ Route Planning Solution

2018-07-12 globenewswire
LONDON, July 12, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announces that Ontex UK, one of the world’s leading suppliers of disposable personal hygiene products, has improved its UK home delivery service and fleet utilization with the Descartes route planning solution. The system was implemented by Descartes’ United by Design Partner, PDMC Logistics.
DSGX DSG

0
Descartes Acquires Velocity Mail

2018-06-25 globenewswire
WATERLOO, Ontario, June 25, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired certain assets of Velocity Mail, an electronic transportation network that provides global air carriers with mail and parcel shipment scanning and tracking solutions.
DSGX DSG

0
Logistics Service Provider B+S Logistik Achieves Rapid Ecommerce Growth using Descartes pixi* Warehouse Management Solution

2018-06-07 globenewswire
MUNICH, Germany, June 07, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that B+S Logistik (B+S GmbH Logistik und Dienstleistungen), a leading German logistics service provider (LSP), has expanded its contract logistics business with new business-to-consumer (B2C) ecommerce operations using the Descartes pixi* warehouse management solution (WMS) to support order fulfillment in fashion, food distribution and other segments.
DSGX DSG

0
Vigilant Enhances Global Trade Compliance Managed Services with Content Solutions from Descartes

2018-05-08 globenewswire
WATERLOO, Ontario, May 08, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Vigilant Global Trade Services, specialists in providing global trade compliance managed services programs to Fortune 100 companies and others, is using Descartes CustomsInfo™ and Descartes MK Denied Party Screening™ solutions to help ensure their clients comply with ever-changing global trade regulations.
DSGX DSG

0
Descartes Sets Date to Announce First Quarter Fiscal 2019 Financial Results

2018-05-02 globenewswire
WATERLOO, Ontario, May 02, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, is scheduled to report its first quarter fiscal 2019 financial results after market close on Wednesday, May 30, 2018.
DSGX DSG

0
Active Nutrition International Takes PowerBar and Dymatize Online Using the Descartes pixi* Warehouse Management Solution

2018-04-09 globenewswire
MUNICH, Germany, April 09, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Munich-based Active Nutrition International GmbH has launched ecommerce channels in Germany and Austria using the Descartes pixi* warehouse management solution (WMS) to support order fulfillment for its PowerBar and Dymatize sports nutrition brands via two new online marketplaces, www.
DSGX DSG

0
U.S. Commercial Service Helps Companies Expand Globally with Descartes Datamyne Solution

2018-03-20 globenewswire
MIAMI, March 20, 2018 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that the U.S. Commercial Service, a business unit of the International Trade Administration (ITA) in the U.S. Department of Commerce, is using the Descartes Datamyne™ global trade data solution to produce in-depth market research to help U.
DSGX DSG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSX:DSG / Descartes Sys on message board site Silicon Investor.

Descartes Systems, DSG/TSE DSGX E-Business- web-based supply chain managment
HDSG - Hudson Classic Grill Disc Graphics (DSGR)